Era-Net TRANSCAN-4 (MOH): Translational Research on Cancer Metabolism- Multidisciplinary Approaches for Diagnosis and Treatment (Pre-Proposals)

Consortia of minimum of 3 (and a maximum 6) partners from at least 3 different eligible countries (see in the call)

Aims of the call:

The anticipated outcome of the call is the development of innovative, personalised approaches for cancer diagnosis, patient stratification, and treatment, grounded in a deeper mechanistic understanding of metabolic alterations in cancer.

Proposals must address at least one of the aims:

Aim 1: Enabling better cancer diagnostics and monitoring through metabolic biomarkers

Novel metabolic biomarkers and technologies offer major opportunities for earlier cancer detection, improved patient stratification and more accurate monitoring of treatment response and disease progression.

Aim 2: Intercepting metabolic vulnerabilities to improve precision medicine

Metabolic reprogramming in cancer creates unique dependencies that can be exploited therapeutically. Tumours often develop distinct metabolic signatures, shaped by oncogenic mutations, which drive tumour initiation, progression, therapy resistance, and metastasis. These metabolic adaptations open the door to precision medicine approaches that target defined metabolic vulnerabilities with tailored interventions.

Funding for the Israeli partner: up to 140K Euro for 3 years (160K Euro for coordinator).
* A short abstract and budget should be sent to the Ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272, 1588). 

https://transcan.eu/news-and-resources/updates/preliminary-announcement-upcoming-call-jtc-2026.kl